Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study

Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis

(2016) Matthew J. Armstrong et al.   JOURNAL OF HEPATOLOGY

Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?

(2016) Amalia Gastaldelli et al.   JOURNAL OF HEPATOLOGY

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

(2016)   JOURNAL OF HEPATOLOGY

Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Common Pathophysiologic Mechanisms

(2015) Chiara Saponaro et al.   Current Diabetes Reports

Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System

(2015) Giuseppe Daniele et al.   DIABETES

Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease

(2015) Chiara Rosso et al.   HEPATOLOGY

Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis

(2015) Laura J Carbone et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Hepatic portal vein denervation impairs oral glucose tolerance but not exenatide’s effect on glycemia

(2014) Viorica Ionut et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis

(2014) M. J. Armstrong et al.   DIABETES OBESITY & METABOLISM

GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody

(2014) Charles Pyke et al.   ENDOCRINOLOGY

Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight

(2014) Laurie L. Baggio et al.   JOURNAL OF CLINICAL INVESTIGATION

Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in nondiabetic rats

(2014) Kosuke Tanaka   WORLD JOURNAL OF GASTROENTEROLOGY

GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance

(2014) Jennifer Taher et al.   Molecular Metabolism

Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action

(2013) Jonathan E. Campbell et al.   Cell Metabolism

Long-Term Effects of Bariatric Surgery on Meal Disposal and  -Cell Function in Diabetic and Nondiabetic Patients

(2013) S. Camastra et al.   DIABETES

Nonalcoholic Fatty Liver Disease: Current Issues and Novel Treatment Approaches

(2013) Romina Lomonaco et al.   DRUGS

Exenatide, a Glucagon-like Peptide-1 Receptor Agonist, Acutely Inhibits Intestinal Lipoprotein Production in Healthy Humans

(2012) Changting Xiao et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Direct effect of GLP-1 infusion on endogenous glucose production in humans

(2012) M. Seghieri et al.   DIABETOLOGIA

GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic MaleApoE−/−Mice

(2012) Naim Panjwani et al.   ENDOCRINOLOGY

Nonalcoholic steatohepatitis versus steatosis: Adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism

(2012) Giovanni Musso et al.   HEPATOLOGY

Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: A pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study

(2012) Lauren N. Bell et al.   HEPATOLOGY

Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4

(2011) Scott E. Kanoski et al.   ENDOCRINOLOGY

Effect of Exenatide on Splanchnic and Peripheral Glucose Metabolism in Type 2 Diabetic Subjects

(2011) E. Cersosimo et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Glucagon like-peptide 1 receptor and the liver

(2011) Jens Pedersen et al.   LIVER INTERNATIONAL

Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis

(2011) Gianluca Svegliati-Baroni et al.   LIVER INTERNATIONAL

A simple index of lipid overaccumulation is a good marker of liver steatosis

(2010) Giorgio Bedogni et al.   BMC GASTROENTEROLOGY

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

(2010) Nitika Arora Gupta et al.   HEPATOLOGY

Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

(2009) Amy G. Shah et al.   Clinical Gastroenterology and Hepatology

Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis

(2009) Amalia Gastaldelli et al.   HEPATOLOGY

Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes

(2008) Antonio Cervera et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

The Glucagon-Like Peptide-1 Receptor Regulates Endogenous Glucose Production and Muscle Glucose Uptake Independent of Its Incretin Action

(2008) Julio E. Ayala et al.   ENDOCRINOLOGY